Financial PerformanceACADIA Pharmaceuticals is valued reasonably for a company generating over $1 billion in annual sales from two approved products.
Patent ProtectionThe District Court of Delaware ruled in Acadia's favor on the patent infringement case, extending Nuplazid's exclusivity into 2038.
Regulatory ApprovalThe opportunity in Rett syndrome is viewed as underappreciated by investors, with potential for European approval and positive developments in the US.